Chinese Clinical Oncology
• 论著 • Previous Articles Next Articles
LIU Delin,SUN Weili,WU Yuan,LIU Peiyan
Received:
Revised:
Online:
Published:
Abstract: Objective To observe the efficacy and toxicity of combination regimen contains lobaplatin in treatment of advanced metastatic breast cancer.Methods From January 2010 to May 2012,47 patients with advanced metastatic breast cancer were enrolled in this study. Lobaplatin(30mg/m2) combined with another chemotherapeutic agents were given to patients. Twentyone to twentyeight days was a cycle.The efficacy and side effects were evaluated after at least two cycles of chemotherapy. Results Therapeutic efficacy and adverse reactions could be evaluated in all patients with no CR patient,13 cases of PR,22 cases of SD and 12 cases of PD.The response rate (RR) was 27.7% and the disease control rate (DCR) was 74.5%.Stratification analysis by ER, HER-2 status or second-line and third/more than thirdline chemotherapy, no significant differences were found between the DCR and RR. Thirtysix patients had progressed at the deadline of follow-up. The median time to progression was 4.7 months(95%CI:4.1-5.3 months).The main side effects were myelosuppression,fatigue and gastrointestinal reaction,which were mosty in grade 1-2 and alleviated by symptomatic treatment. Conclusion Combination regimen contains lobaplatin for advanced metastatic breast cancer patients is effective and well tolerated.
LIU Delin,SUN Weili,WU Yuan,LIU Peiyan. Clinical observation of combination regimen contains lobaplatin for advanced metastatic breast cancer[J].Chinese Clinical Oncology, 2013, 18(2): 129-.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: http://manu65.magtech.com.cn/Jwk3_lczlxzz/EN/
http://manu65.magtech.com.cn/Jwk3_lczlxzz/EN/Y2013/V18/I2/129
Cited